
The FAIR-HF2 trial enrolled 1105 HFrEF patients with iron deficiency to evaluate IV ferric carboxymaltose. Compared to prior trials, this cohort had greater use of SGLT2 inhibitors (24%) and ARNIs (38%). Baseline characteristics—age, comorbidities, iron indices—were largely similar to earlier studies. These updated demographics offer insight into evolving HFrEF management and treatment applicability.
Like
Save
Share